AR116112A2 - COMPOSICIÓN FARMACÉUTICA LÍQUIDA CON ESTABILIDAD EN EL LARGO PLAZO DE UN FACTOR VON WILLEBRAND (rVWF) RECOMBINANTE - Google Patents
COMPOSICIÓN FARMACÉUTICA LÍQUIDA CON ESTABILIDAD EN EL LARGO PLAZO DE UN FACTOR VON WILLEBRAND (rVWF) RECOMBINANTEInfo
- Publication number
- AR116112A2 AR116112A2 ARP190102509A ARP190102509A AR116112A2 AR 116112 A2 AR116112 A2 AR 116112A2 AR P190102509 A ARP190102509 A AR P190102509A AR P190102509 A ARP190102509 A AR P190102509A AR 116112 A2 AR116112 A2 AR 116112A2
- Authority
- AR
- Argentina
- Prior art keywords
- rvwf
- group
- pharmaceutical composition
- long
- term stability
- Prior art date
Links
- 239000007788 liquid Substances 0.000 title abstract 2
- 230000007774 longterm Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 108010047303 von Willebrand Factor Proteins 0.000 title abstract 2
- 102100036537 von Willebrand factor Human genes 0.000 title abstract 2
- 229960001134 von willebrand factor Drugs 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000003381 stabilizer Substances 0.000 abstract 3
- 239000004094 surface-active agent Substances 0.000 abstract 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- 239000006172 buffering agent Substances 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 abstract 1
- 108010081391 Ristocetin Proteins 0.000 abstract 1
- 229930006000 Sucrose Natural products 0.000 abstract 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 1
- 239000007983 Tris buffer Substances 0.000 abstract 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 abstract 1
- 230000004520 agglutination Effects 0.000 abstract 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 239000000872 buffer Substances 0.000 abstract 1
- 239000001110 calcium chloride Substances 0.000 abstract 1
- 229910001628 calcium chloride Inorganic materials 0.000 abstract 1
- BGTFCAQCKWKTRL-YDEUACAXSA-N chembl1095986 Chemical compound C1[C@@H](N)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]([C@H]1C(N[C@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(C(=C(O)C=4)C)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@@H](C(=O)N3)[C@H](O)C=3C=CC(O4)=CC=3)C(=O)N1)C(O)=O)=O)C(C=C1)=CC=C1OC1=C(O[C@@H]3[C@H]([C@H](O)[C@@H](O)[C@H](CO[C@@H]5[C@H]([C@@H](O)[C@H](O)[C@@H](C)O5)O)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@H](O)[C@@H](CO)O3)O)C4=CC2=C1 BGTFCAQCKWKTRL-YDEUACAXSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000006179 pH buffering agent Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 abstract 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 abstract 1
- 229940068968 polysorbate 80 Drugs 0.000 abstract 1
- 229920000053 polysorbate 80 Polymers 0.000 abstract 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 abstract 1
- 229950004257 ristocetin Drugs 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 239000001509 sodium citrate Substances 0.000 abstract 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 abstract 1
- 239000005720 sucrose Substances 0.000 abstract 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
Abstract
Composición farmacéutica líquida con estabilidad en el largo plazo de un Factor von Willebrand (rVWF) recombinante que comprende: (a) un rVWF; (b) un agente amortiguador, (c) una o más sales; (d) un agente estabilizante; y (e) un tensioactivo; donde dicho rVWF es capaz de causar la aglutinación de plaquetas estabilizadas en presencia de ristocetina; donde dicho rVWF comprende un polipéptido seleccionado del grupo integrado por: a) la secuencia de aminoácidos expuesta en la SEC ID Nº 3; y b) un polipéptido codificado por el polinucleótido que se establece en la SEC ID Nº 1; en donde dicho buffer está compuesto de un agente amortiguador de pH en un rango de 0,1 mM hasta 500 mM y donde el pH está en un rango de 2,0 hasta 12,0, en donde dicho agente amortiguador se selecciona del grupo que consiste en citrato de sodio, glicina, histidina, Tris, y combinaciones de estos agentes; donde dicha sal está a una concentración de 1 hasta 500 mM, en donde dicha sal se selecciona del grupo que consiste en cloruro de calcio y cloruro de sodio; donde dicho agente estabilizante está a una concentración de 0,1 a 1000 mM y se selecciona del grupo integrado por manitol, sacarosa, trehalosa, rafinosa, y combinaciones de estos agentes estabilizantes; y donde dicho tensioactivo está a una concentración de aproximadamente 0,01 g/L a 0,5 g/L, en donde dicho tensioactivo es polisorbato-80.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1741807P | 2007-12-28 | 2007-12-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR116112A2 true AR116112A2 (es) | 2021-03-31 |
Family
ID=40602549
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105761A AR070061A1 (es) | 2007-12-28 | 2008-12-29 | Filtracion por contrapresion de proteinas |
| ARP190102509A AR116112A2 (es) | 2007-12-28 | 2019-09-03 | COMPOSICIÓN FARMACÉUTICA LÍQUIDA CON ESTABILIDAD EN EL LARGO PLAZO DE UN FACTOR VON WILLEBRAND (rVWF) RECOMBINANTE |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105761A AR070061A1 (es) | 2007-12-28 | 2008-12-29 | Filtracion por contrapresion de proteinas |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US7959809B2 (es) |
| EP (2) | EP2242479B1 (es) |
| JP (4) | JP5027310B2 (es) |
| KR (3) | KR101839278B1 (es) |
| CN (1) | CN101909599B (es) |
| AR (2) | AR070061A1 (es) |
| AT (1) | ATE525062T1 (es) |
| AU (1) | AU2008345218B2 (es) |
| BR (1) | BRPI0821599A2 (es) |
| CA (1) | CA2709781C (es) |
| DK (1) | DK2242479T3 (es) |
| ES (1) | ES2377038T3 (es) |
| HK (1) | HK1150750A1 (es) |
| HR (1) | HRP20110927T1 (es) |
| NZ (2) | NZ600053A (es) |
| PL (1) | PL2242479T3 (es) |
| PT (1) | PT2242479E (es) |
| SG (1) | SG187411A1 (es) |
| SI (1) | SI2242479T1 (es) |
| WO (1) | WO2009086296A2 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2242479T3 (pl) * | 2007-12-28 | 2012-02-29 | Baxalta Inc | Filtracja białek z zastosowaniem przeciwciśnienia |
| TWI469992B (zh) | 2008-08-28 | 2015-01-21 | Baxter Int | 濃縮剪切靈敏生物聚合物的方法 |
| US10100594B2 (en) * | 2013-06-27 | 2018-10-16 | Ge Oil & Gas Uk Limited | Control system and a method for monitoring a filter in an underwater hydrocarbon well |
| JP6397933B2 (ja) * | 2014-01-20 | 2018-09-26 | ユーシービー バイオファルマ エスピーアールエル | 固体形態の医薬組成物の再構成のための方法 |
| JP7348610B1 (ja) | 2023-04-10 | 2023-09-21 | ソブエクレー株式会社 | 植物生育用鉄供給剤 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2624373C2 (de) * | 1976-05-31 | 1983-02-03 | Arnold Dr. 8782 Karlstadt Seufert | Verfahren zur Herstellung von steril filtriertem Kryopräzipilat mit einer Anreicherung des Faktors VIII |
| US5047154A (en) * | 1983-03-10 | 1991-09-10 | C.P.C. Engineering Company | Method and apparatus for enhancing the flux rate of cross-flow filtration systems |
| SE443075B (sv) * | 1984-06-01 | 1986-02-17 | Alfa Laval Agri Int | Forfarande och anordning for framstellning av mjolkkoncentrat genom membranfiltrering |
| ATE64956T1 (de) * | 1984-06-14 | 1991-07-15 | Ciba Geigy Ag | Verfahren zur herstellung von thrombininhibitoren. |
| CA1339946C (en) * | 1987-03-31 | 1998-07-07 | Michael J. Griffith | Ultrapurification process for polypeptides |
| US4774323A (en) * | 1987-06-29 | 1988-09-27 | Rorer Pharmaceutical Corporation | Purification of von Willebrand Factor solutions using gel permeation chromatography |
| DE3730868A1 (de) | 1987-09-15 | 1989-03-23 | Henkel Kgaa | Verfahren zur abtrennung von biotechnisch hergestellten wertstoffen aus einer fermenterbruehe durch querstrom-mikro- und/oder ultrafiltration |
| SE9003452L (sv) | 1990-10-30 | 1992-05-01 | Teinvall Sjoeberg & Broberg Ab | Saett och anordning vid vaetskefiltrering |
| CH687055A5 (de) * | 1993-12-03 | 1996-09-13 | Bucher Guyer Ag Masch | Verfahren und Vorrichtung zum Eindicken von Fest/Fluessig-Gemischen mittels Membrantechnologie. |
| US5525144A (en) * | 1995-04-20 | 1996-06-11 | A/G Technology Corporation | Tangential flow filtering and separating |
| AT403764B (de) * | 1996-03-15 | 1998-05-25 | Immuno Ag | Stabiler faktor viii/vwf-komplex |
| DE69610227T2 (de) * | 1996-07-10 | 2001-01-04 | American Nat Red Cross Washing | Verfahren zur selektiver trennung organischer komponenten aus biologischen flüssigkeiten |
| US5888401A (en) * | 1996-09-16 | 1999-03-30 | Union Camp Corporation | Method and apparatus for reducing membrane fouling |
| AT406867B (de) * | 1997-02-27 | 2000-10-25 | Immuno Ag | Verfahren zur gewinnung von hochreinem vwf oder faktor viii/vwf-komplex |
| US5947689A (en) * | 1997-05-07 | 1999-09-07 | Scilog, Inc. | Automated, quantitative, system for filtration of liquids having a pump controller |
| FR2772381B1 (fr) | 1997-12-15 | 2001-06-08 | Lab Francais Du Fractionnement | Procede de preparation par filtration d'une solution de facteur viii securisee viralement |
| US6139878A (en) | 1998-04-27 | 2000-10-31 | Aventis Behring, Llc | Method for preparing a diafiltered stabilized blood product |
| WO2000016872A1 (en) * | 1998-09-21 | 2000-03-30 | Purdum Howard E | Methods and apparatus for processing temperature sensitive materials |
| DE19906379B4 (de) * | 1999-02-16 | 2006-05-18 | Huss, Manfred | Herstellung eines aggregierten Molkenproteinprodukts |
| WO2005016455A2 (en) * | 2003-08-14 | 2005-02-24 | D. Collen Research Foundation Vzw | Antibodies against factor viii with modified glycosylation in the variable region |
| US6485762B1 (en) * | 1999-07-26 | 2002-11-26 | Cornell Research Foundation, Inc. | Microfiltration of skim milk for cheese making and whey proteins |
| US6623781B2 (en) * | 1999-07-26 | 2003-09-23 | Cornell Research Foundation, Inc. | Microfiltration of skim milk for cheese making and whey proteins |
| DE10211227A1 (de) * | 2002-03-13 | 2003-10-02 | Aventis Behring Gmbh | Verfahren zur Rekonstitution von Iyophilisierten Proteinen |
| SE522048C2 (sv) | 2002-05-17 | 2004-01-07 | Hemapure Ab | Anordning och system för filtrering av blod |
| EP1553113B1 (en) * | 2002-06-17 | 2008-11-19 | Asahi Kasei Kuraray Medical Co., Ltd. | Biocompatible polymer and filter for selectively eliminating leucocytes using the same |
| ES2214967B1 (es) | 2003-03-06 | 2005-06-16 | Probitas Pharma, S.A | Procedimiento para la eliminacion de virus en soluciones de fibrinogeno y fibrinogeno obtenido por dicho procedimiento. |
| FR2861395B1 (fr) | 2003-10-23 | 2006-02-17 | Lab Francais Du Fractionnement | Facteur viii viralement securise a faible teneur en multimeres superieurs |
| DE602006003420D1 (de) * | 2005-04-11 | 2008-12-11 | Crucell Holland Bv | Virusreinigung mit ultrafiltration |
| PL2242479T3 (pl) * | 2007-12-28 | 2012-02-29 | Baxalta Inc | Filtracja białek z zastosowaniem przeciwciśnienia |
-
2008
- 2008-12-22 PL PL08867937T patent/PL2242479T3/pl unknown
- 2008-12-22 EP EP08867937A patent/EP2242479B1/en not_active Revoked
- 2008-12-22 PT PT08867937T patent/PT2242479E/pt unknown
- 2008-12-22 AT AT08867937T patent/ATE525062T1/de active
- 2008-12-22 KR KR1020177015613A patent/KR101839278B1/ko active IP Right Grant
- 2008-12-22 AU AU2008345218A patent/AU2008345218B2/en active Active
- 2008-12-22 EP EP11176408A patent/EP2392317A1/en not_active Withdrawn
- 2008-12-22 SI SI200830465T patent/SI2242479T1/sl unknown
- 2008-12-22 KR KR1020107015781A patent/KR101748878B1/ko active IP Right Grant
- 2008-12-22 JP JP2010540839A patent/JP5027310B2/ja active Active
- 2008-12-22 CN CN2008801239915A patent/CN101909599B/zh active Active
- 2008-12-22 US US12/341,733 patent/US7959809B2/en active Active
- 2008-12-22 ES ES08867937T patent/ES2377038T3/es active Active
- 2008-12-22 BR BRPI0821599-5A patent/BRPI0821599A2/pt not_active Application Discontinuation
- 2008-12-22 DK DK08867937.8T patent/DK2242479T3/da active
- 2008-12-22 CA CA2709781A patent/CA2709781C/en active Active
- 2008-12-22 KR KR1020187006765A patent/KR101915445B1/ko active IP Right Grant
- 2008-12-22 SG SG2012096392A patent/SG187411A1/en unknown
- 2008-12-22 WO PCT/US2008/088005 patent/WO2009086296A2/en active Application Filing
- 2008-12-22 NZ NZ600053A patent/NZ600053A/xx not_active IP Right Cessation
- 2008-12-22 NZ NZ586316A patent/NZ586316A/en not_active IP Right Cessation
- 2008-12-29 AR ARP080105761A patent/AR070061A1/es active IP Right Grant
-
2010
- 2010-08-20 US US12/860,424 patent/US8075782B2/en active Active
- 2010-08-20 US US12/860,411 patent/US8075781B2/en active Active
-
2011
- 2011-05-09 HK HK11104588.7A patent/HK1150750A1/xx unknown
- 2011-11-16 US US13/297,587 patent/US8454833B2/en active Active
- 2011-12-12 HR HR20110927T patent/HRP20110927T1/hr unknown
-
2012
- 2012-05-07 JP JP2012105696A patent/JP5466263B2/ja active Active
-
2014
- 2014-01-23 JP JP2014009986A patent/JP5925817B2/ja active Active
-
2016
- 2016-03-03 JP JP2016040641A patent/JP2016106131A/ja active Pending
-
2019
- 2019-09-03 AR ARP190102509A patent/AR116112A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR116112A2 (es) | COMPOSICIÓN FARMACÉUTICA LÍQUIDA CON ESTABILIDAD EN EL LARGO PLAZO DE UN FACTOR VON WILLEBRAND (rVWF) RECOMBINANTE | |
| AR069989A1 (es) | Formulaciones de vwf recombinantes | |
| AR118012A2 (es) | Una composición farmacéutica estable liofilizada de un factor von willebrand recombinante | |
| ES2654102T3 (es) | Formulaciones líquidas para conjugado de C-CSF de acción prolongada | |
| PE20191716A1 (es) | Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos | |
| ECSP077246A (es) | Formulaciones Estabilizadoras | |
| RU2017106159A (ru) | Состав фактора viii | |
| AR072796A1 (es) | ESTABILIZADOR Y COMPOSICION DE VACUNA QUE COMPRENDE UNO O MAS FLAVIVIRUS VIVOS ATENUADOS O QUIMÉRICOS. MÉTODO DE ESTABILIZACIoN. KIT. | |
| AU9078401A (en) | Antimicrobial peptides and methods of use | |
| RU2017101667A (ru) | Фармацевтические композиции | |
| BR9714434A (pt) | Formulações de interferon liquidas estáveis | |
| HRP20110242T1 (hr) | Formulacija s fuzijskim proteinom glp-1-fc | |
| JP2011508742A5 (es) | ||
| RU2009101226A (ru) | Составы антагониста vegf, подходящие для интравитреального введения | |
| AR080428A1 (es) | Formulaciones liquidas estabilizadas contentivas de anticuerpos | |
| AR108631A1 (es) | Formulación de neurotoxinas | |
| AR079946A1 (es) | Formulaciones liquidas para conjugados de accion prolongada de eritropoyetina | |
| AR100268A1 (es) | Formulación líquida que comprende compuesto neutralizante de gm-csf | |
| AR039123A1 (es) | Composicion farmaceutica estable que contiene el factor viii | |
| EA200970981A1 (ru) | Пептидная смесь в качестве стабилизатора вина | |
| BR112019011769A2 (pt) | composição de anticorpo anti-c5 aquosa estável | |
| DE602004025100D1 (de) | Stabilisierung von proteinen in lösung | |
| RU2011122629A (ru) | Водная композиция, содержащая фолликулостимулирующий гормон | |
| RU2019130728A (ru) | Жидкая композиция антитела против TNF альфа | |
| RU2015144076A (ru) | Композиции рекомбинантного фактора viii |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |